GLS and leukemia: When used in combination with drugs that increase ROS formation, like arsenic trioxide or homoharringtonine, inhibitors of glutaminase (GLS), the first enzyme in glutaminolysis, significantly decreased the viability of AML cells and leukemia burden in treated mice (52).